Early Diagnosis of Kidney Cancer Using CAIX-Targeted PET Imaging An Exploratory Study Evaluating Safety and Effectiveness of 68Ga18F-CAIX-LT-BCH in Adults

What this Trial Is About

Renal carcinoma is a common malignant tumor worldwide, with increasing cases and deaths projected by 2025. Early non-invasive diagnosis of clear cell renal cell carcinoma ccRCC is important to improve outcomes. This trial investigates the use of CAIX-targeted PET imaging probes, which bind to a protein highly expressed in most ccRCC tumors, to help with early and accurate detection of renal cancer. The study uses a small molecule called RESCA-CAIX-LT that is modified to be stable in the body and labeled with radioactive substances 68Ga or 18F. These probes are administered intravenously at a dose of about 0.05-0.1 mCikg. After injection, whole-body dynamic and static PETCT scans are performed to visualize tumors. The imaging is done using advanced PETCT equipment and may include delayed scans for unclear lesions. Participants will be patients with renal cancer or suspected cases who are scheduled for biopsy or surgery soon. Researchers will measure the uptake of the imaging probe in tumor lesions to assess diagnostic performance. The trial includes safety monitoring, imaging evaluations, and follow-up to determine how well the probe detects tumors. Participants will be involved in scanning procedures and assessments over the study period.

Clinical Application of CAIX-Targeted PET Imaging in Tumors